Replies to post #192704 on Innovation Pharmaceuticals Inc (IPIX)

[Amatuer17]

http://www.ipharminc.com/press-release/2017/3/27/cellceutix-reports-very-encouraging-interim-analysis-of-phase-2-drug-candidate-brilacidin-for-severe-oral-mucositis-om-in-head-and-neck-cancer-patients-high-potential-for-preventative-treatment


Primary Endpoints of the Brilacidin OM trial are:

• Incidence of Severe OM (WHO Grade ≥ 3) experienced during radiation therapy (across 7 weeks) by patients with Head and Neck Cancer receiving a cumulative radiation dose of at least 55 Gy in the course of their chemoradiation treatment
• Safety and Tolerability of Brilacidin

A Secondary Endpoint included in the Interim Analysis is:

• Duration of Severe OM (WHO Grade ≥ 3)

[rmzport]

Daub... To be certain follow-ups do extend out. My comment was that dosing would conclude September 23 based on the criteria laid out in the trial protocol. I view that is an important time with BP monitoring so closely. Also, as I recall the trial was set up to administer to 60 patients. By this mornings PR 61 patients will be administered Brilacidin. Another very good sign!